A Continuation Study of Prophylactic and On-demand Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP) With TAK-755
A Continuation Study of Prophylactic and On-demand Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP) With TAK-755
The purpose of this study is to assess safety and efficacy of long-term use of TAK-755 in the
 prophylactic and on-demand treatment of participants with severe cTTP.
This is a follow-up study to the Phase 3 pivotal study (281102 [NCT03393975]) and will
 comprise of two treatment cohorts (Prophylactic and On-demand) consisting of TAK-755 naïve
 and non- naïve participants with a total duration of 6 years. A total of 88 participants will
 be enrolled in this study (upto 68 participants who have completed 281102 [NCT03393975] study
 [non-naïve participants] and at least 20 TAK-755-naïve participants [participants who are
 naïve to TAK-755 or participants who participated in some part of study 281102 but did not
 complete the study]). Participants on prophylactic regimen will be able to opt for treatment
 in a home setting by caregiver or self-infusion.
Inclusion Criteria:

 -The participant will not be considered eligible for the study without meeting all of the
 criteria below:

 Participants who have completed TAK-755 Phase 3 pivotal study 281102 (NCT03393975) and who
 meet all of the following criteria are eligible for this study:

 -  Participants or legally authorized representative has provided signed informed consent
 (greater than or equal to (>=) 18 years of age) and/or assent form (less than (<) 18
 years of age).

 -  Participant 0 to 70 years of age at the time of screening of the 281102 (NCT03393975)
 study.

 -  Participant has been diagnosed with severe congenital ADAMTS-13 deficiency.

 -  Participant does not display any severe thrombotic thrombocytopenic purpura (TTP)
 signs (platelet count < 100,000/ microliter (mcL) and elevation of lactate
 dehydrogenase (LDH) (greater than) > 2 × upper limit of normal (ULN) at screening
 (prophylactic cohort only).

 -  Participants >= 16 years of age must have a Karnofsky score >= 70 percent (%) and
 participants < 16 years of age must have a Lansky score >= 80%.

 -  If female of childbearing potential, participant presents with a negative serum or
 urine pregnancy test confirmed not more than 7 days before the first IP administration
 and agrees to employ adequate birth control measures for the duration of the study and
 to undergo quarterly pregnancy testing.

 -  Sexually active males must use an accepted and effective method of contraception
 during the treatment and until a minimum of 16 days after the last dose administered.

 -  Participant is willing and able to comply with the requirements of the protocol.

 TAK-755 naïve participants and non-naïve on-demand cohort participants:

 TAK-755 naïve participants can only be enrolled in this continuation after enrollment of
 the adult participants in the prophylactic arm of TAK-755 Phase 3 pivotal study 281102
 (NCT03393975) has been completed. TAK-755 naive pediatric participants can be enrolled
 after enrollment of the respective age cohort into the pivotal Phase 3 study 281102
 (NCT03393975) has been completed.TAK-755 naïve participants and participants who were
 enrolled into the on-demand cohort of theTAK-755 Phase 3 pivotal study 281102 (NCT03393975)
 who meet ALL of the following criteria are eligible for this study:

 -  Participant is naïve to TAK-755 or was enrolled into the on-demand cohort of the
 TAK-755 Phase 3 pivotal study 281102 (NCT03393975) for treatment of an acute event but
 did not receive prophylactic treatment.

 -  Participant or legally authorized representative has provided signed informed consent
 (>= 18 years of age) and/or assent form (< 18 years of age).

 -  Participant is 0 to 70 years of age at the time of screening.

 -  Participant has been diagnosed with severe congenital ADAMTS-13 deficiency defined as:

 -  Confirmed by molecular genetic testing, documented in participant history or at
 screening, and

 -  ADAMTS-13 activity < 10% as measured by the fluorescence resonance energy
 transfer (FRETS)-VWF73 assay, documented in participant history or at screening.
 Participants currently receiving standard of care prophylactic therapy may exceed
 10% ADAMTS-13 activity at screening.

 -  Participants currently receiving prophylactic therapy will be screened immediately
 prior to their usual prophylactic infusion.

 -  Participant does not display any severe TTP signs (platelet count < 100,000/microliter
 (mcL) and elevation of LDH > 2 × ULN) at screening (prophylactic cohort only).

 -  Participants >= 16 years of age must have a Karnofsky score >= 70% and participants <
 16 years of age must have a Lansky score >= 80%.

 -  Participants is hepatitis C virus negative (HCV-) as confirmed by antibody or
 polymerase chain reaction testing OR HCV positive (HCV+) if their disease is chronic
 but stable.

 -  If female of childbearing potential, participant presents with a negative serum or
 urine pregnancy test confirmed not more than 7 days before the first IP administration
 and agrees to employ adequate birth control measures for the duration of the study and
 to undergo quarterly pregnancy testing.

 -  Sexually active males must use an accepted and effective method of contraception
 during treatment and until a minimum of 16 days after the last dose administered.

 -  Participant is willing and able to comply with the requirements of the protocol.

 Exclusion Criteria:

 The participants will be excluded from the study if any of the following exclusion criteria
 are met.

 For both participants who have completed TAK-755 Phase 3 pivotal study (281102) and TAK 755
 naïve participants:

 -  Participant has been diagnosed with any other TTP-like disorder (microangiopathic
 hemolytic anemia), including immune-mediated TTP.

 -  Known life-threatening hypersensitivity reaction, including anaphylaxis, to the parent
 molecule ADAMTS-13, hamster protein, or other constituents of TAK-755.

 -  Participant has a medical history or presence of a functional ADAMTS-13 inhibitor at
 screening.

 -  Participant has a medical history of a genetic or acquired immune deficiency that
 would interfere with the assessment of product immunogenicity, including participants
 who are human immunodeficiency virus-positive with an absolute cluster of
 differentiation 4 (CD4) count < 200/ cubic millimeter (mm^3) or who are receiving
 chronic immunosuppressive drugs.

 -  Participant has a history of significant neurological events, such as major stroke,
 indicating that a relapse might have severe consequences, as judged by the
 investigator.

 -  Participant has been diagnosed with severe cardiovascular disease (New York Heart
 Association classes 3 to 4).

 -  Participant with end stage renal disease requiring chronic dialysis.

 -  Participant has been diagnosed with hepatic dysfunction, as evidenced by, but not
 limited to, any of the following:

 -  Serum alanine aminotransferase >= 2 × ULN

 -  Severe hypoalbuminemia < 24 gram per liter (g/L)

 -  Portal vein hypertension (e.g., presence of otherwise unexplained splenomegaly,
 history of esophageal varices).

 -  In the opinion of the investigator, the participant has another clinically significant
 concomitant disease that may pose additional risks for the participant.

 -  Participant has been treated with an immunomodulatory drug, excluding topical
 treatment (e.g., ointments, nasal sprays), within 30 days prior to enrollment. Use of
 corticosteroids in conjunction with administration of fresh frozen plasma to prevent
 allergic manifestations is permitted.

 -  Participant has an acute illness (e.g., influenza, flu-like syndrome, allergic
 rhinitis/conjunctivitis, bronchial asthma) at the time of screening (prophylactic
 cohort only).

 -  Participant is receiving or anticipates receiving another investigational drug and/or
 interventional drug within 30 days before enrollment.

 -  Participant has a history of drug and/or alcohol abuse within the last 2 years.

 -  Participant has a progressive fatal disease and/or life expectancy of lesser than or
 equal to (<=) 3 months.

 -  Participant is identified by the investigator as being unable or unwilling to
 cooperate with study procedures.

 -  Participant suffers from a mental condition rendering him/her unable to understand the
 nature, scope, and possible consequences of the study and/or evidence of an
 uncooperative attitude.

 -  Participant is a family member or employee of the sponsor or investigator.

 -  If female, participant is pregnant or lactating at the time of enrollment.